Manager TitleAgeSince
Chief Executive Officer - 22/03/2024
Director of Finance/CFO - 31/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman - 01/01/2024
Director/Board Member - 01/01/2021
Director/Board Member - 22/03/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-1.10% - - 29.94L
-2.47%-1.90%+15.75%-25.65% 1.73TCr
+1.64%-5.48%+0.79%+91.39% 156.65Cr
-4.60%-3.35%-31.66%-79.61% 118.52Cr
+1.29%-4.72%-37.01%+15.19% 100Cr
-0.64%+2.18%-28.81%-52.65% 64Cr
-1.79%-5.76%-41.68%-57.20% 53Cr
+0.66%-0.74%+44.77%-53.97% 44Cr
0.00%+0.64%-54.33%-58.66% 38Cr
+1.09%+7.51%-18.78%-22.74% 36Cr
Average -0.00%-0.85%-16.77%-27.10% 259.87Cr
Weighted average by Cap. -1.80%-4.11%+6.42%-21.30%
Logo NEOS AB
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Company’s product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Employees
13
  1. Stock Market
  2. Stocks
  3. NEOD Stock